GENMAB Inactive Instrument
Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 19.8B 2.88B 3.92B | Sales 2025 * | 23.62B 3.44B 4.68B | Capitalization | 132B 19.21B 26.13B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.68B 682M 928M | Net income 2025 * | 6.63B 966M 1.31B | EV / Sales 2024 * | 5.33 x |
| Net cash position 2024 * | 26.36B 3.84B 5.22B | Net cash position 2025 * | 33.63B 4.9B 6.67B | EV / Sales 2025 * | 4.16 x |
| P/E ratio 2024 * |
29.9
x | P/E ratio 2025 * |
21.5
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
| Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B | |
| -24.95% | 8.45B |
